Timothy P. Kelly - 20 Feb 2026 Form 4 Insider Report for Caribou Biosciences, Inc. (CRBU)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
24 Feb 2026, 20:54:41 UTC
Prior SEC filing
21 Feb 2025
Next SEC filing
27 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Barbara G. McClung, as attorney-in-fact

Key filing fact

Timothy P. Kelly filed Form 4 for Caribou Biosciences, Inc. (CRBU) on 24 Feb 2026.

Key facts

  • This page summarizes Timothy P. Kelly's Form 4 filing for Caribou Biosciences, Inc. (CRBU).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 24 Feb 2026, 20:54.

Change

  • Previous filing in this sequence was filed on 21 Feb 2025.
  • Current net transaction value: -$6,168.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001754067 Primary reporting owner

Kelly Timothy P

Relationship
Chief Technology Officer
Address
C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY
Signature
/s/ Barbara G. McClung, as attorney-in-fact
Signature date
24 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRBU transaction

Common Stock

Award

Transaction value
$0
Shares
+45,000
Change %
+120%
Price
$0.000000
Shares after
82,500
Date
20 Feb 2026
Ownership
Direct
Footnotes
F1
CRBU transaction

Common Stock

Sale

Transaction value
$6,168
Shares
-3,147
Change %
-3.8%
Price
$1.96
Shares after
79,353
Date
24 Feb 2026
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRBU transaction Derivative

Option to purchase Common Stock

Award

Transaction value
$0
Shares
+202,500
Change %
Price
$0.000000
Shares after
202,500
Date
20 Feb 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
202,500
Exercise price
$1.80
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.

Footnote F2

Reflects the number of shares of common stock that were sold pursuant to the Issuer's mandatory sell-to-cover policy for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person.

Footnote F3

1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .